Evidence map›Paper›PMID 38276092›Full record

ArticleJournal of clinical medicine2024

Real-Life Multicenter Experience of Venetoclax in Combination with Hypomethylating Agents in Previously Untreated Adult Patients with Acute Myeloid Leukemia in Greece.

Theodora Chatzilygeroudi, Ismini Darmani, Natali El Gkotmi, Pinelopi Vryttia, Stavroula Douna, Anthi Bouchla, Vasiliki Labropoulou, Maria Kotsopoulou, Argiris Symeonidis, Maria Pagoni and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Theodora ChatzilygeroudiHematology Division, Department of Internal Medicine, School of Health Sciences, Faculty of Medicine, University of Patras, 30100 Patras, Greece.
Ismini DarmaniHematology Department, Evaggelismos General Hospital, 10676 Athens, Greece.
Natali El GkotmiHematology Department, Evaggelismos General Hospital, 10676 Athens, Greece.
Pinelopi VryttiaHematology Unit, Second Department of Internal Medicine, and Research Institute, Medical School, University General Hospital "Attikon", National and Kapodistrian University of Athens, 12462 Athens, Greece.
Stavroula DounaHematology Department, Metaxa General Hospital, 18537 Peiraeus, Greece.
Anthi BouchlaHematology Unit, Second Department of Internal Medicine, and Research Institute, Medical School, University General Hospital "Attikon", National and Kapodistrian University of Athens, 12462 Athens, Greece.
Vasiliki LabropoulouHematology Division, Department of Internal Medicine, School of Health Sciences, Faculty of Medicine, University of Patras, 30100 Patras, Greece.
Maria KotsopoulouHematology Department, Metaxa General Hospital, 18537 Peiraeus, Greece.
Argiris SymeonidisHematology Division, Department of Internal Medicine, School of Health Sciences, Faculty of Medicine, University of Patras, 30100 Patras, Greece.ORCID 0000-0002-3685-3473
Maria PagoniHematology Department, Evaggelismos General Hospital, 10676 Athens, Greece.
Vasiliki PappaHematology Unit, Second Department of Internal Medicine, and Research Institute, Medical School, University General Hospital "Attikon", National and Kapodistrian University of Athens, 12462 Athens, Greece.
Sotirios G PapageorgiouHematology Unit, Second Department of Internal Medicine, and Research Institute, Medical School, University General Hospital "Attikon", National and Kapodistrian University of Athens, 12462 Athens, Greece.ORCID 0000-0002-3376-837X
National and Kapodistrian University of Athens · GRAgios Pavlos General Hospital · GRUniversity of Patras · GRMetaxa Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe landscape of first-line treatment for acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy has changed remarkably after venetoclax approval. Accumulating real-world data further apprises us with more knowledgeable use. To assess the efficacy and safety challenges in the real-life setting of the combination of hypomethylated agent (HMA) and venetoclax, we conducted a multi-center retrospective study.

methodsForty adult AML patients treated with the combination of HMA and venetoclax as a first-line treatment after full approval (2020) were included. To confirm VIALE-A results, this group was compared to a historical cohort of 17 chemotherapy-ineligible AML patients treated with HMA monotherapy before 2020.

resultsThe combination of HMA-venetoclax achieved a composite complete response rate of 86.8% (

conclusionsEvidently, venetoclax-HMA yields high response rates and profound survival benefits in real life and has changed our approach to alternative chemotherapy options.

Indexed as

AMLfrontline treatmentHMAshypomethylating agentsreal-world datavenetoclax

Identifiers

PMID38276092
PMCPMC10816211
OpenAlexW4391026114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.